821 The combination of a trastuzumab ISAC and pertuzumab augments anti-tumor efficacy in multiple HER2+ tumor models relative to trastuzumab plus pertuzumab by Pearson, Cecelia I, Luo, Andrew, Henning, Karla A, Lucas, Anthony, Omstead, David, McEachin, Katelynn A, Ponath, Paul D, Chapin, Steven J, Ackerman, Shelley E, Perez, Edith A, Kim, Han K, Alonso, Michael N

Get full text

1147-D Preclinical characterization of a novel claudin 18.2 targeting-ISAC with robust potency and acceptable safety profile by Kim, Han K, Monnier, Justin, Fu, Chi-Ling, Zhou, Matthew, Melrose, Jennifer E, Dao, Hung, Ponath, Paul D, McEachin, Katelynn A, Omstead, David T, Kreder, Cindy, Chun, Stefan, Lee, Ying Yueh, Grgich, Rachel, Lin, Tracey J, Walker, Joshua A, Henning, Karla A, Kudirka, Romas, Ackerman, Shelley E, Carrera, Diane, Chapin, Steven J, Mallet, William, Jackson, Dowdy, Gao, Changshou, Alonso, Michael N

Get full text

Abstract 2964: Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042 by Kenkel, Justin A., Xiao, Fang, Ho, Po Y., Nolin, Jess L., Gadkari, Rishali K., Torrez, Laughing Bear, Omstead, David T., McEachin, Katelynn A., Ptacek, Jason, Grgich, Rachel, Pearson, Cecelia I., Chun, Stefan, Kreder, Cindy L., Henning, Karla A., Kim, Han K., Xu, Lu, Chapin, Steven J., Alonso, Michael N., Ackerman, Shelley E.

Get full text